Influence of lipid-lowering drugs on inflammation: what is yet to be done?

Area of Science:

• Cardiovascular Medicine
• Inflammation Biology
• Pharmacology

Background:

• Atherosclerosis is a chronic inflammatory condition linked to cardiovascular events.
• C-reactive protein is a key clinical marker for inflammation.
• Current lipid-lowering therapies primarily focus on LDL cholesterol reduction but leave residual risk.

Purpose of the Study:

• To review the anti-inflammatory effects of various lipid-lowering drugs.
• To examine the impact of these drugs on C-reactive protein (CRP).
• To explore the relationship between anti-inflammatory actions and reduced cardiovascular events, especially for statins.

Main Methods:

• Literature review of lipid-lowering agents including statins, ezetimibe, fibrates, niacin, PCSK9 inhibitors, bempedoic acid, ethyl eicosapentaenoic acid, and antisense oligonucleotides.
• Focus on studies measuring C-reactive protein as an inflammatory marker.
• Analysis of how drug-induced inflammation reduction correlates with cardiovascular outcomes.

Main Results:

• Statins demonstrate anti-inflammatory effects beyond LDL-C reduction.
• Several other lipid-lowering drugs also exhibit varying degrees of impact on inflammation markers like CRP.
• Persistent inflammation may contribute to recurrent cardiovascular events despite optimal lipid control.

Conclusions:

• Lipid-lowering drugs possess pleiotropic effects, including significant anti-inflammatory actions.
• Targeting residual inflammation with these agents may be crucial for further reducing cardiovascular event recurrence.
• The anti-inflammatory properties of statins likely contribute to their cardiovascular benefits.